Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

GSK plc (GSK)

35.13   -0.36 (-1.01%) 02-02 16:00
Open: 35.43 Pre. Close: 35.49
High: 35.61 Low: 34.865
Volume: 5,433,256 Market Cap: 71,915(M)

Technical analysis

as of: 2023-02-02 4:12:36 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 41.8     One year: 48.82
Support: Support1: 34.82    Support2: 34.22
Resistance: Resistance1: 35.78    Resistance2: 41.8
Pivot: 35.27
Moving Average: MA(5): 35.25     MA(20): 35.12
MA(100): 33.24     MA(250): 38.35
MACD: MACD(12,26): 0     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 64     %D(3): 64
RSI: RSI(14): 50
52-week: High: 46.97  Low: 28.46
Average Vol(K): 3-Month: 5,204 (K)  10-Days: 4,699 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ GSK ] has closed above bottom band by 32.9%. Bollinger Bands are 69.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 35.82 - 35.96 35.96 - 36.12
Low: 34.72 - 34.87 34.87 - 35.04
Close: 35.21 - 35.45 35.45 - 35.73

Company Description

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Headline News

Thu, 02 Feb 2023
GSK plc (NYSE:GSK) Q4 2022 Earnings Call Transcript - Yahoo Finance

Thu, 02 Feb 2023
GSK rises Thursday, still underperforms market - MarketWatch

Thu, 02 Feb 2023
GSK Wins Approval for CKD Anemia Drug – with Conditions - BioSpace

Thu, 02 Feb 2023
Pharmalittle: GSK CEO warns U.K. pharma industry is at a 'tipping point'; Gavi tussles with vaccine makers over refunds - STAT

Thu, 02 Feb 2023
GSK's anemia drug Jesduvroq scores FDA green light - FiercePharma

Wed, 01 Feb 2023
U.S. FDA approves GSK's anemia drug for patients on dialysis - Reuters

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 2,520 (M)
Shares Float 19,580 (M)
% Held by Insiders 0 (%)
% Held by Institutions 14.1 (%)
Shares Short 15,870 (K)
Shares Short P.Month 13,970 (K)

Stock Financials

EPS 2.88
EPS Est Next Qtl 0
EPS Est This Year 2.89
EPS Est Next Year 2.84
Book Value (p.s.) 5.94
Profit Margin (%) 12.2
Operating Margin (%) 23.4
Return on Assets (ttm) 6.5
Return on Equity (ttm) 24.7
Qtrly Rev. Growth 18.7
Gross Profit (p.s.) 8.99
Sales Per Share 14.77
EBITDA (p.s.) 4.4
Qtrly Earnings Growth -40.3
Operating Cash Flow 10,510 (M)
Levered Free Cash Flow -9,890 (M)

Stock Valuations

PE Ratio 12.19
PEG Ratio 0.9
Price to Book value 5.91
Price to Sales 2.37
Price to Cash Flow 8.42

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2022-01-12
Ex-Dividend Date 2021-11-17
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.